Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder

IMPORTANCE: In 2017, the US Food and Drug Administration (FDA) approved a monthly injectable form of buprenorphine, extended-release buprenorphine; published data show that extended-release buprenorphine is effective compared with no treatment, but its current cost is higher and current retention is...

Descripción completa

Detalles Bibliográficos
Autores principales: Flam-Ross, Juliet M., Marsh, Elizabeth, Weitz, Michelle, Savinkina, Alexandra, Schackman, Bruce R., Wang, Jianing, Madushani, R. W. M. A., Morgan, Jake R., Barocas, Joshua A., Walley, Alexander Y., Chrysanthopoulou, Stavroula A., Linas, Benjamin P., Assoumou, Sabrina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500382/
https://www.ncbi.nlm.nih.gov/pubmed/37703018
http://dx.doi.org/10.1001/jamanetworkopen.2023.29583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500382/
https://www.ncbi.nlm.nih.gov/pubmed/37703018
http://dx.doi.org/10.1001/jamanetworkopen.2023.29583

Ejemplares similares